# US 2017/0253613 A1 · Novel chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0253613 A1
- Document ID: US20170253613A1
- Status: Published application
- Kind: A1
- Application number: 15/506,941
- Filed: 2015-08-27
- Published: 2017-09-07
- Earliest claimed: 2014-08-27
- Assignees: Prexton Therapeutics SA
- Applicants: Prexton Therapeutics SA
- Inventors: Delphine CHARVIN; Baptiste MANTEAU; Vincent POMEL; François CONQUET
- Web page: https://patentgrep.com/patent/US20170253613A1

## CPC

- C07D 495/04: Ortho-condensed systems
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/02: Nutrients, e.g. vitamins, minerals
- A61P 3/08: for glucose homeostasis (pancreatic hormones A61P5/48)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/00: Drugs for disorders of the endocrine system
- A61P 5/14: of the thyroid hormones, e.g. T3, T4
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/32: Alcohol-abuse
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 29/02: without antiinflammatory effect
- A61P 31/18: for HIV
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a novel chromone oxime derivative of formula (I), which is a modulator of nervous system receptors sensitive to glutamate and, furthermore, presents an advantageously high brain penetration upon oral administration. The invention also relates to a pharmaceutical composition containing this compound, and to its use for the treatment or prevention of conditions associated with altered glutamatergic signalling and/or functions, or conditions which can be affected by alteration of glutamate level or signalling, particularly acute and chronic neurological and/or psychiatric disorders.

## Claims

### Claim 1

A compound of the following formula (I):
or a pharmaceutically acceptable salt, solvate or prodrug thereof.

### Claim 2 (depends on 1)

The compound of claim 1, wherein said compound has the (E)-configuration at the oxime group comprised in formula (I).

### Claim 3 (depends on 1, 2)

The compound of claim 1 or 2, wherein the pharmaceutically acceptable salt is a hydrochloride salt.

### Claim 4 (depends on 1, 2, 3)

The compound of any one of claims 1 to 3 for use as a medicament.

### Claim 5 (depends on 1, 2, 3)

A pharmaceutical composition comprising the compound of any one of claims 1 to 3 and a pharmaceutically acceptable excipient.

### Claim 6 (depends on 1, 2, 3, 5)

The compound of any one of claims 1 to 3 or the pharmaceutical composition of claim 5 for use in the treatment or prevention of a condition associated with altered glutamatergic signalling and/or functions, or a condition which can be affected by alteration of glutamate level or signalling.

### Claim 7 (depends on 6)

The compound or the pharmaceutical composition for use according to claim 6, wherein said condition associated with altered glutamatergic signalling and/or functions, or said condition which can be affected by alteration of glutamate level or signalling is selected from: dementias, parkinsonism and movement disorders, acute or chronic pain, anxiety disorders, schizophrenia, mood disorders, endocrine and metabolic diseases, diabetes, disorders of the endocrine glands, hypoglycaemia, or cancers.

### Claim 8 (depends on 7)

The compound or the pharmaceutical composition for use according to claim 7, wherein said dementias are selected from: dementias of the Alzheimer's type (DAT); Alzheimer's disease; Pick's disease; vascular dementias; Lewy-body disease; dementias due to metabolic, toxic and deficiency diseases, including alcoholism, hypothyroidism, and vitamin B12 deficiency; AIDS-dementia complex; Creutzfeld-Jacob disease; or atypical subacute spongiform encephalopathy.

### Claim 9 (depends on 7)

The compound or the pharmaceutical composition for use according to claim 7, wherein said parkinsonism and movement disorders are selected from: Parkinson's disease; multiple system atrophy; progressive supranuclear palsy; corticobasal degeneration; hepatolenticular degeneration; chorea, including Huntington's disease and hemiballismus; athetosis; dystonias, including spasmodic torticollis, occupational movement disorder, and Gilles de la Tourette syndrome; tardive or drug induced dyskinesias, including levodopa-induced dyskinesia; tremor; or myoclonus.

### Claim 10 (depends on 7)

The compound or the pharmaceutical composition for use according to claim 7, wherein said anxiety disorders are selected from: panic disorders; phobias; obsessive-compulsive disorders; stress disorders, including post-traumatic stress disorder; or generalized anxiety disorders.

### Claim 11 (depends on 7)

The compound or the pharmaceutical composition for use according to claim 7, wherein said mood disorders are selected from depressive disorders or bipolar disorders.

### Claim 12 (depends on 1, 2, 3, 5)

The compound of any one of claims 1 to 3 or the pharmaceutical composition of claim 5 for use in the treatment or prevention of Parkinson's disease.

### Claim 13 (depends on 6, 7, 8, 9, 10, 11, 12)

The compound or the pharmaceutical composition for use according to any one of claims 6 to 12, wherein said compound or said pharmaceutical composition is to be administered orally.

### Claim 14 (depends on 1, 2, 3)

Use of the compound of any one of claims 1 to 3 for the preparation of a medicament for the treatment or prevention of a condition associated with altered glutamatergic signalling and/or functions, or a condition which can be affected by alteration of glutamate level or signalling.

### Claim 15 (depends on 14)

The use of claim 14, wherein said condition associated with altered glutamatergic signalling and/or functions, or said condition which can be affected by alteration of glutamate level or signalling is selected from: dementias, parkinsonism and movement disorders, acute or chronic pain, anxiety disorders, schizophrenia, mood disorders, endocrine and metabolic diseases, diabetes, disorders of the endocrine glands, hypoglycaemia, or cancers.

### Claim 16 (depends on 15)

The use of claim 15, wherein said dementias are selected from: dementias of the Alzheimer's type (DAT); Alzheimer's disease; Pick's disease; vascular dementias; Lewy-body disease; dementias due to metabolic, toxic and deficiency diseases, including alcoholism, hypothyroidism, and vitamin B12 deficiency; AIDS-dementia complex; Creutzfeld-Jacob disease; or atypical subacute spongiform encephalopathy.

### Claim 17 (depends on 15)

The use of claim 15, wherein said parkinsonism and movement disorders are selected from: Parkinson's disease; multiple system atrophy; progressive supranuclear palsy; corticobasal degeneration; hepatolenticular degeneration; chorea, including Huntington's disease and hemiballismus; athetosis; dystonias, including spasmodic torticollis, occupational movement disorder, and Gilles de la Tourette syndrome; tardive or drug induced dyskinesias, including levodopa-induced dyskinesia; tremor; or myoclonus.

### Claim 18 (depends on 15)

The use of claim 15, wherein said anxiety disorders are selected from: panic disorders; phobias; obsessive-compulsive disorders; stress disorders, including post-traumatic stress disorder; or generalized anxiety disorders.

### Claim 19 (depends on 15)

The use of claim 15, wherein said mood disorders are selected from depressive disorders or bipolar disorders.

### Claim 20 (depends on 1, 2, 3)

Use of the compound of any one of claims 1 to 3 for the preparation of a medicament for the treatment or prevention of Parkinson's disease.

### Claim 21 (depends on 14, 15, 16, 17, 18, 19, 20)

The use of any one of claims 14 to 20, wherein said medicament is to be administered orally.

### Claim 22 (depends on 1)

A method of treating a condition associated with altered glutamatergic signalling and/or functions, or a condition which can be affected by alteration of glutamate level or signalling, the method comprising the administration of the compound of claim 1 to a subject in need thereof.

### Claim 23 (depends on 22)

The method of claim 22, wherein said condition associated with altered glutamatergic signalling and/or functions, or said condition which can be affected by alteration of glutamate level or signalling is selected from the group consisting of: dementias, parkinsonism and movement disorders, acute or chronic pain, anxiety disorders, schizophrenia, mood disorders, endocrine and metabolic diseases, diabetes, disorders of the endocrine glands, hypoglycaemia, and cancers.

### Claim 24 (depends on 23)

The method of claim 23, wherein said dementias are selected from the group consisting of: dementias of the Alzheimer's type (DAT); Alzheimer's disease; Pick's disease; vascular dementias; Lewy-body disease; dementias due to metabolic, toxic and deficiency diseases, including alcoholism, hypothyroidism, and vitamin B12 deficiency; AIDS-dementia complex; Creutzfeld-Jacob disease; and atypical subacute spongiform encephalopathy.

### Claim 25 (depends on 23)

The method of claim 23, wherein said parkinsonism and movement disorders are selected from the group consisting of: Parkinson's disease; multiple system atrophy; progressive supranuclear palsy; corticobasal degeneration; hepatolenticular degeneration; chorea, including Huntington's disease and hemiballismus; athetosis; dystonias, including spasmodic torticollis, occupational movement disorder, and Gilles de la Tourette syndrome; tardive or drug induced dyskinesias, including levodopa-induced dyskinesia; tremor; and myoclonus.

### Claim 26 (depends on 23)

The method of claim 23, wherein said anxiety disorders are selected from the group consisting of: panic disorders; phobias; obsessive-compulsive disorders; stress disorders, including post-traumatic stress disorder; and generalized anxiety disorders.

### Claim 27 (depends on 23)

The method of claim 23, wherein said mood disorders are selected from the group consisting of depressive disorders and bipolar disorders.

### Claim 28 (depends on 22)

The method of claim 22, wherein the method comprises orally administering said compound to said subject.

### Claim 29 (depends on 22)

The method of claim 22, wherein said subject is a human.

### Claim 30 (depends on 1)

A method of treating Parkinson's disease, the method comprising the administration of the compound of claim 1 to a subject in need thereof.

### Claim 31 (depends on 30)

The method of claim 30, wherein the method comprises orally administering said compound to said subject.

### Claim 32 (depends on 30)

The method of claim 30, wherein said subject is a human.
